Literature DB >> 35992329

Resolving the heterogeneous tumor-centric cellular neighborhood through multiplexed, spatial paracrine interactions in the setting of immune checkpoint blockade.

Rachel L G Maus1,2, Alexey L Leontovich3, Raymond M Moore3, Laura Becher2, Wendy K Nevala1, Thomas J Flotte4, Ruifeng Guo4, Jill Schimke1, Betty A Dicke1, Yiyi Yan1, Svetomir N Markovic1,2.   

Abstract

Direct interactions between tumor and immune cells mediate the antitumor effect of all modern cancer immunotherapeutic agents. Simultaneously, tumor cells have evolved mechanisms of evasion including the downregulation of HLA-I potentially disrupting the mechanism of action employed by many immune checkpoint inhibitors. And yet the in situ interplay between these cells within the tumor immune microenvironment (TIME) remains elusive. Recent advances in histologic multiplex bioimaging platforms have enabled in-depth molecular characterization of single cells within spatially-preserved and clinically archived tumor tissues. Herein, we applied multiplex immunofluorescence (MxIF) to excisional lymph node biopsies from 14 patients with metastatic melanoma who experienced clear objective responses to immunotherapy (7 complete response; 7 progressive disease) to determine distinguishing features of the TIME in the pretreatment setting. Distinct regions of the TIME were evaluated using 35 proteins probing tumor, immune and vasculature components across 323 fields of view. Single cell compositional analysis confirmed established prognostic immune cell types including increased prevalence of cytotoxic T cells within the tumor core FOVs of responders. Integrating single cell quantification with the spatial arrangement of cellular neighborhoods surrounding tumor cells revealed novel, spatial immune signatures capable of stratifying TIME based on clinical response. Our analysis revealed dynamic cellular composition of the TCCN based on anatomical subregion, functional expression of HLA-I by the index tumor cell and ultimately clinical response to immunotherapy. Overall, this study provides an analytical framework to resolve the cellular complexity of the TIME, increasingly relevant to the outcomes of modern cancer immunotherapy.

Entities:  

Year:  2022        PMID: 35992329      PMCID: PMC9390837          DOI: 10.1158/2767-9764.crc-21-0146

Source DB:  PubMed          Journal:  Cancer Res Commun        ISSN: 2767-9764


  34 in total

Review 1.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  How individual species structure diversity in tropical forests.

Authors:  Thorsten Wiegand; C V Savitri Gunatilleke; I A U Nimal Gunatilleke; Andreas Huth
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-16       Impact factor: 11.205

3.  Inferring species interactions in tropical forests.

Authors:  Igor Volkov; Jayanth R Banavar; Stephen P Hubbell; Amos Maritan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-04       Impact factor: 11.205

4.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

Review 5.  ilastik: interactive machine learning for (bio)image analysis.

Authors:  Stuart Berg; Dominik Kutra; Thorben Kroeger; Christoph N Straehle; Bernhard X Kausler; Carsten Haubold; Martin Schiegg; Janez Ales; Thorsten Beier; Markus Rudy; Kemal Eren; Jaime I Cervantes; Buote Xu; Fynn Beuttenmueller; Adrian Wolny; Chong Zhang; Ullrich Koethe; Fred A Hamprecht; Anna Kreshuk
Journal:  Nat Methods       Date:  2019-09-30       Impact factor: 28.547

Review 6.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Authors:  Jonathan J Havel; Diego Chowell; Timothy A Chan
Journal:  Nat Rev Cancer       Date:  2019-03       Impact factor: 60.716

Review 7.  The Lymphatic System: Integral Roles in Immunity.

Authors:  Gwendalyn J Randolph; Stoyan Ivanov; Bernd H Zinselmeyer; Joshua P Scallan
Journal:  Annu Rev Immunol       Date:  2016-11-14       Impact factor: 28.527

8.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

9.  The single-cell pathology landscape of breast cancer.

Authors:  Hartland W Jackson; Jana R Fischer; Vito R T Zanotelli; H Raza Ali; Robert Mechera; Savas D Soysal; Holger Moch; Simone Muenst; Zsuzsanna Varga; Walter P Weber; Bernd Bodenmiller
Journal:  Nature       Date:  2020-01-20       Impact factor: 49.962

10.  CytoMAP: A Spatial Analysis Toolbox Reveals Features of Myeloid Cell Organization in Lymphoid Tissues.

Authors:  Caleb R Stoltzfus; Jakub Filipek; Benjamin H Gern; Brandy E Olin; Joseph M Leal; Yajun Wu; Miranda R Lyons-Cohen; Jessica Y Huang; Clarissa L Paz-Stoltzfus; Courtney R Plumlee; Thomas Pöschinger; Kevin B Urdahl; Mario Perro; Michael Y Gerner
Journal:  Cell Rep       Date:  2020-04-21       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.